Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Uterine Neoplasms 1Urologic Neoplasms 1Kidney Neoplasms 1Kidney Diseases 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Carcinoma 1

Interventions

Sunitinib 4avelumab 2Nutrition Assessment 2Blood Specimen Collection 2Axitinib 2trifluridine tipiracil drug combination 1trebananib 1spartalizumab 1pembrolizumab 1palbociclib 1etelcalcetide hydrochloride 1enzalutamide 1cabozantinib 1bicalutamide 1atezolizumab 1aldesleukin 1Valsartan 1VMBP protocol 1Stents 1Specimen Handling 1Sorafenib 1Sodium Bicarbonate 1Resistance Training 1Receptors, Androgen 1Plasma Exchange 1Pharmaceutical Preparations 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Nephrotomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Diseases × VMBP protocol × Clear all
NCT04300140 2023-10-30

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Aravive, Inc.

Phase 1/2 Terminated
72 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡